Oncodesign announces the selection of its First-in-Class RIPK2 inhibitor drug candidate for auto-immune and inflammatory diseases

17/12/19

DOWNLOAD

Oncodesign: publication of an article presenting promising results for the treatment of stone man syndrome (FOP)

24/10/19

DOWNLOAD

First-half 2019 results

26/09/19

DOWNLOAD

Acceleration in growth in the first half of 2019, with sales rising 52% to €14 million

25/07/19

DOWNLOAD

By closing this message, you consent to our cookies on this device in accordance with our cookie policy unless you have disabled them.